Standardized mortality ratio highest for cancers of lung, head and neck, testes, bladder, Hodgkin lymphoma.
Reduction in trial discussions, trial offers, trial participation seen with one or more comorbidities.
Health expenditure greater for person with 2 diseases simultaneously than for the diseases separately.
Socioeconomic inequalities are widening, but racial gap in cancer mortality narrowing slowly.
Mortality rate lower for habitually active patients and for those who started exercising after diagnosis
41% are not at all familiar with personalized medicine; only 5% say they are very familiar.
Risk for patients in rivaroxaban group reduced during the on-treatment period
Drug targets solid tumors with NTRK gene fusion without a known acquired resistance mutation
Second study shows no significant results for vitamin D supplementation vs placebo.
In addition to health care factors, issues outside of treatment may affect cancer death rates.
Higher risk seen with ACEIs vs angiotensin receptor blockers; risk linked to duration of use
Radiation dose not impacted with light or moderate use of skin treatments, regardless of beam energy, incidence
At 6 months, rates for provoked, unprovoked, cancer-related VTE are 6.8, 6.92, 9.06 per 100 person-years
From 2000 to 2015 screening for breast, cervical, and prostate cancers decreased significantly, whereas screening for colorectal cancer increased significantly.
High-dose monthly supplementation doesn't reduce risk of cancer among middle-aged and older adults.
Over 20 years, a 1-L reduction in alcohol intake was linked to 3.9 percent drop in overall cancer mortality.
Mortality risk linked to complementary medicine mediated by treatment refusal
Incidence rates decreased among men from 2008 to 2014, remained stable among women.
ICU and hospital mortality were lower for patients with cancer versus those without cancer.
Post-traumatic stress symptoms also linked to lower risk of readmission in hospitalized CA patients.
In subgroup analyses, reduced incidence of cancer seen in participants aged younger than 65 years.
Even among those exposed to high radiation doses, one-third not concerned about developing cancer.
Half of meds ID'd in expanded access programs treat cancer; others for metabolic, endocrine diseases
Even patients with mild chronic kidney disease were prevented from participating in clinical trials of drugs for bladder, breast, colorectal, lung, and prostate cancers.
Highest Healthy Eating Index scores associated with decreased overall and cancer-specific mortality.
From 2006 and 2016, smallest increase seen in high Sociodemographic Index countries.
Increased risk of subsequent diabetes independent of traditional diabetes risk factors.
Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment.
Benefit of palliative radiation for bone metastasis across age groups; older age should not preclude tx.
Lower rate of VTE recurrence, but higher clinically relevant non-major bleeding versus dalteparin.
Renal and Urology News Articles
- Low Vitamin D Tied to Risk for Renal Hyperfiltration in Healthy Adults
- Novel Albuminuria Endpoints May Improve CKD Progression Trials
- Overactive Bladder Linked to Prostate Cancer ADT
- Second-Line Antidiabetic Meds May Impact Cardiovascular Risk
- Hemodialysis Patients May Benefit by Staying on Loop Diuretics
- High Uric Acid Predicts AKI, Mortality in Hospitalized Patients
- PCa Phenotype May Predict Response to Immune Checkpoint Blockade
- Roxadustat Effective in Chronic Kidney Disease Patients With Anemia
- Coronary Artery Calcium May Help Predict CVD in South Asians
- American College of Physicians Releases 7th Edition of Ethics Manual
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)